Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study
Enables expansion of ongoing vitiligo clinical study to U.S. investigational sites Topline data anticipated Q4 2027 TORONTO, Oct. 15, 2026 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported that the U.S. Food and Drug Administration (FDA) has cleared the…
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
